TABLE 1:

Clinical features of 12 patients with MCA occlusion

Patient/Age(y)/SexInitial Occlusion SiteUrokinase Dose (U)Time from Onset (min)Occlusion Site after ProcedureNIHSS ScoremRS Score at 3 mo
AdmissionStart of AngiographyEnd of ProcedureInitial24 h3 mo
–1/73/ML M1 proximal480,0004070210FM3231911
–2/70/FL M1 distal480,0006090150FP M425000
–3/70/FR M1 proximal480,0006090160No18200
–4/81/F*L M1 distal540,0004070180FT M32727235
–5/84/ML M1 proximal480,000120165265F M32517DeadDead
–6/66/ML M1 proximal480,00060120180F M425231
–7/70/MR M1 distal360,00065105165No16100
–8/74/ML M1 proximal600,00095130210F M3 C M42013134
–9/74/FL M1 distal360,0004595150P M324500
10/84/ML FP M2 proximal360,0006090180F M3251992
11/78/MR M1 proximal420,000150210300PT M319300
12/71/MR M1 distal480,000120180230P M419500
  • Note.—C indicates central; F, frontal; P, parietal; T, temporal; M1, horizontal segment of the MCA; M2, insular segment of the MCA; M3, opercular segment of the MCA; and M4, cortical segment of the MCA.

  • * Direct puncture.

  • Multiple organ failure.

  • Perforation.